Through the partnership among Sai Life Sciences, Agility Life Sciences and Centrix Pharma Solutions, customers will have access to integrated drug substance and drug product development, helping them move efficiently from pre-clinical studies to First-In-Human (FIH) clinical trials and beyond.
Agility Life Sciences | 09/10/2025 | By Dineshwori
Conduit and Agility to Develop Enhanced Formulations for its Autoimmune Pipeline
Conduit has developed a series of novel, advantageous solid forms of all its autoimmune pipeline assets, each protected by newly established composition-of-matter intellectual property (IP).
Agility Life Sciences | 23/01/2025 | By Aishwarya | 294
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy